# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:MDT) with a Hold and raises the price target from $85 t...
Barclays analyst Matt Miksic maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $104 to $105.
- Reuters
Oppenheimer analyst Steven Lichtman maintains Medtronic (NYSE:MDT) with a Perform and raises the price target from $92 to $94.
Piper Sandler analyst Matt O'Brien maintains Medtronic (NYSE:MDT) with a Neutral and raises the price target from $85 to...
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.
Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and raises the price target from $105 t...